Neisseria

Novotech Publishes Whitepaper on Infectious Diseases Clinical Trials, Revealing Over 7,000 Trials Launched Worldwide

Retrieved on: 
Tuesday, November 7, 2023
Knowledge, RSV, Genetically modified bacteria, Staphylococcus aureus, Viral disease, Attention, Immunodeficiency, Infection, Vaccine, Zika fever, Fungal infection, HIV, Disease, Global Jurist of the Year Award, Candidiasis, Public, Hepatitis, Patient, Aspergillosis, Fine chemical, Pharmaceutical industry, Neisseria

BOSTON, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Novotech, the leading Asia Pacific centred biotech CRO with global execution capabilities, today published the latest 2023 global clinical trial environment whitepaper focused on infectious diseases.

Key Points: 
  • BOSTON, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Novotech, the leading Asia Pacific centred biotech CRO with global execution capabilities, today published the latest 2023 global clinical trial environment whitepaper focused on infectious diseases.
  • This helps to contribute to the advancement of knowledge of the clinical trials industry.
  • The Infectious Diseases - Global Clinical Trial Environment (2018~2023) whitepaper offers a comprehensive assessment of the global clinical trial landscape.
  • Other infectious diseases (16%), including protozoal infections, targeted a variety of agents that caused considerable morbidity, particularly in resource-limited areas.

“Gonorrhea Alert” Intensifies Globally, says AHF

Retrieved on: 
Wednesday, July 26, 2023
Public Policy, Government, Pharmaceutical, AIDS, Health, Infectious Diseases, Communications, Social Activism, Advocacy Group Opinion, Infection, AHF, STI, Neisseria gonorrhoeae, Gonorrhea, Multimedia, HIV, AIDS Healthcare Foundation, Syphilis, World Health Organization, Disease, Vaccine, Birth control, Neisseria

Neisseria gonorrhea is exceptionally dangerous due to its resistance to multiple treatments, including new antibiotics being developed specifically for this pathogen.

Key Points: 
  • Neisseria gonorrhea is exceptionally dangerous due to its resistance to multiple treatments, including new antibiotics being developed specifically for this pathogen.
  • “Condoms are still the most cost-effective way to prevent gonorrhea, syphilis, and other STIs, including HIV – a fact people everywhere should be made aware of.
  • That starts with information campaigns at all levels of government in all countries and ensuring adequate access to free or affordable condoms.
  • Over 82 million new cases of Neisseria gonorrhea are reported in adults between the ages of 15 to 49 annually, according to the World Health Organization.

New Research Shows Promising Possibilities for At-Home Testing to Detect Sexually Transmitted Infections

Retrieved on: 
Tuesday, July 25, 2023
Vagina, Laboratory, Kaiser Permanente, Human papillomavirus infection, STI, Urine, Infection, Los Angeles County Department of Health Services, Research, Temperature, Neisseria gonorrhoeae, Doctor of Philosophy, Centers for Disease Control and Prevention, Chlamydia trachomatis, Public health, Rectum, Cervical cancer, Los Angeles County Department of Public Health, Physician, HPV, Patient, Throat, Birth control, Mineral oil, Neisseria, Chlamydia

ANAHEIM, Calif., July 25, 2023 /PRNewswire/ -- Self-collected tests performed similarly to provider-collected tests for detecting common sexually transmitted infections (STIs), according to research presented today at the 2023 AACC Annual Scientific Meeting & Clinical Lab Expo. These findings could enable discreet new testing options that expand access to screening.

Key Points: 
  • ANAHEIM, Calif., July 25, 2023 /PRNewswire/ -- Self-collected tests performed similarly to provider-collected tests for detecting common sexually transmitted infections (STIs), according to research presented today at the 2023 AACC Annual Scientific Meeting & Clinical Lab Expo.
  • However, more research is needed to establish the reliability of self-collected tests.
  • For 15 study participants, the researchers evaluated 5 self-collected swabs to assess variability in swabs taken from the same individual.
  • The researchers were motivated to increase inclusivity and access to STI testing by exploring additional options for self-collection and home testing.

Birmingham spinout to develop 20-minute test following surge in sexually transmitted infections

Retrieved on: 
Thursday, June 8, 2023
Infection, Linearity, National Institute for Health and Care Research, UK Health Security Agency, DNA, University, STI, MSM, Neisseria, Woman, Multimedia, Gonorrhea, University of Birmingham, Chlamydia trachomatis, Patient, Security agency, NIHR, World Health Organization, Vertically transmitted infection, Diagnosis, WHO, WSW, Birth control, Vaccine, Chlamydia

Brendan Farrell, Chairman of Linear Diagnostics, said: "For STIs, the rapidity of the testing procedure is key, as patients prefer to get test results quickly and start treatment immediately.

Key Points: 
  • Brendan Farrell, Chairman of Linear Diagnostics, said: "For STIs, the rapidity of the testing procedure is key, as patients prefer to get test results quickly and start treatment immediately.
  • Its work brings people from across the world to Birmingham, including researchers, teachers and more than 8,000 international students from over 150 countries.
  • The World Health Organization has noted the rapid increase in multi-drug resistant gonorrhoea, with all confirmed treatment failures except one being pharyngeal infections affecting the throat.
  • The UK Health Security Agency warned this week of a surge in gonorrhoea cases, with a 50% increase between 2021 and 2022.

Birmingham spinout to develop 20-minute test following surge in sexually transmitted infections

Retrieved on: 
Thursday, June 8, 2023
Infection, Linearity, National Institute for Health and Care Research, UK Health Security Agency, DNA, University, STI, MSM, Neisseria, Woman, Gonorrhea, University of Birmingham, Chlamydia trachomatis, Patient, Security agency, NIHR, World Health Organization, Vertically transmitted infection, Diagnosis, WHO, WSW, Vaccine, Chlamydia

The University of Birmingham is ranked amongst the world's top 100 institutions.

Key Points: 
  • The University of Birmingham is ranked amongst the world's top 100 institutions.
  • Its work brings people from across the world to Birmingham, including researchers, teachers and more than 8,000 international students from over 150 countries.
  • The World Health Organization has noted the rapid increase in multi-drug resistant gonorrhoea, with all confirmed treatment failures except one being pharyngeal infections affecting the throat.
  • The UK Health Security Agency warned this week of a surge in gonorrhoea cases, with a 50% increase between 2021 and 2022.

Visby Medical™ Receives FDA Clearance and CLIA Waiver for Second Generation Sexual Health Test for Women

Retrieved on: 
Tuesday, March 14, 2023
SAN, Pharmacy, Patient, Korea Disease Control and Prevention Agency, Food, Visby, STI, Associate, Neisseria gonorrhoeae, PCR, Gonorrhea, Trichomonas vaginalis, Risk, Prevention, Polymerase chain reaction, Woman, Workflow, Education, Health, Chlamydia trachomatis, MD, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Diagnosis, CLIA, POC, Stanford University, Pelvic inflammatory disease, Pharmaceutical industry, Birth control, Operation, Medicine, Neisseria, Trichomonas, Chlamydia

The Visby Medical Sexual Health test is a fast, polymerase chain reaction (PCR) diagnostic test for the detection of sexually transmitted infections (STIs) caused by Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis in women.

Key Points: 
  • The Visby Medical Sexual Health test is a fast, polymerase chain reaction (PCR) diagnostic test for the detection of sexually transmitted infections (STIs) caused by Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis in women.
  • The CLIA-waived, Sexual Health POC test provides accurate results in under 30 minutes, enabling clinicians to test, talk and accurately treat with confidence in a single patient visit.
  • "The Visby Sexual Health Test has been a game changer for us.
  • The Visby test is a win-win, helping fight antibiotic resistance as well as the spread of untreated infection, while empowering patients to engage health services with greater confidence."

Thermo Fisher Scientific Launches TrueMark STI Select Panel

Retrieved on: 
Wednesday, February 8, 2023
Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Research, Infectious Diseases, Alternative Energy, Environment, Energy, Science, STI, Thermo Fisher Scientific, Neisseria gonorrhoeae, Applied Biosystems, Korea Disease Control and Prevention Agency, Mycoplasma, PCR, MagMax, Genetic testing, Trichomonas vaginalis, Ribonuclease P, Chlamydia trachomatis, CDC, Syphilis, Genetic, Gonorrhea, Polymerase chain reaction, Mycoplasma genitalium, Vaccine, Neisseria, Chlamydia, Trichomonas

Thermo Fisher Scientific, the world leader in serving science, today announced the launch of its Applied Biosystems TrueMark STI Select Panel, a polymerase chain reaction (PCR) research use only test designed to detect Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis and Mycoplasma genitalium in one test, as well as RNase P, included as a human internal control.

Key Points: 
  • Thermo Fisher Scientific, the world leader in serving science, today announced the launch of its Applied Biosystems TrueMark STI Select Panel, a polymerase chain reaction (PCR) research use only test designed to detect Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis and Mycoplasma genitalium in one test, as well as RNase P, included as a human internal control.
  • The Applied Biosystems TrueMark STI Select Panel simultaneously tests for the four common STIs on the same panel, helping labs save time that would have been otherwise needed to run each on their own.
  • The TrueMark STI Select Panel is sold as a combo kit, which includes the STI panel assay and master mix; positive controls are also included for added accuracy and efficiency.
  • For more information on Thermo Fisher’s TrueMark STI Panel, please visit: https://www.thermofisher.com/truemarkstiselectpanel
    For Research Use Only.

Amid National Surge in Sexually Transmitted Infections binx health Announces Launch of Reagent Rental Program for Decentralized, Rapid, Point-of-Care Testing Platform for Chlamydia and Gonorrhea

Retrieved on: 
Tuesday, November 1, 2022
Medical Devices, Health, Technology, Infectious Diseases, Hospitals, Other Technology, Arm, DNA, Korea Disease Control and Prevention Agency, PCR, Binx, HIV, Partnership, Organization, Gonorrhea, EMR, Health minister, Risk, Program, Chlamydia trachomatis, Infection, Pregnancy, NG, Public health, Polymerase chain reaction, Technology, CT, University, LIS, Point-of-care testing, Woman, FDA, Patient, Man, STI, Health equity, CDC, Center, Female, Male, CLIA, Diagnosis, Medical imaging, Pharmaceutical industry, Neisseria, Chlamydia

This program eliminates all upfront instrument costs, enabling access to rapid testing and helping pave the way to better health outcomes.

Key Points: 
  • This program eliminates all upfront instrument costs, enabling access to rapid testing and helping pave the way to better health outcomes.
  • The company has begun accepting pre-orders under its early access program for Q1 deliveries.
  • Please contact binx today to participate in the early access program and reserve a binx io at [email protected] or visit www.binx-io.com .
  • For a symptomatic male patient with a chlamydia negative test result, further testing with a laboratory-based molecular test is recommended.

Lucira Health Reports Pilot Study Interim Results for Chlamydia and Gonorrhea Assays

Retrieved on: 
Thursday, September 29, 2022
Chlamydia trachomatis, MPH, National, Risk, Neisseria gonorrhoeae, Infection, COVID-19, Woman, STI, Organic acid, LAMP, Cepheid variable, Neisseria, Ministry, Urinary tract infection, Growth, Private Securities Litigation Reform Act, Lucira, Maintenance, Forward-looking statement, U.S. Securities and Exchange Commission, Technology, University of California, San Francisco, Female, POCT, San Francisco, CDC, Annual report, Nasdaq, UC, Research, Security (finance), GLOBE, Marketing, Sexually transmitted infection, Pharmaceutical industry, Birth control, MD, Chlamydia, Health

EMERYVILLE, Calif., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (Nasdaq: LHDX) (Lucira Health or Lucira), a medical technology company, today announced interim results of a pilot study to evaluate the performance of their combined Chlamydia trachomatis and Neisseria gonorrhoeae assays integrated into the instrument-free at-home Lucira molecular test platform.

Key Points: 
  • EMERYVILLE, Calif., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (Nasdaq: LHDX) (Lucira Health or Lucira), a medical technology company, today announced interim results of a pilot study to evaluate the performance of their combined Chlamydia trachomatis and Neisseria gonorrhoeae assays integrated into the instrument-free at-home Lucira molecular test platform.
  • The ongoing study has tested over 150 female participants with positive performance results of the integrated chlamydia and gonorrhea tests and will be published in the near future.
  • Lucira is integrating these STI assays into its easy-to-use fully untethered test platform that requires no external equipment and produces rapid molecular results on-the-spot.
  • Its an honor to have world renowned principal investigator, Deborah Dean, MD, MPH, leading the clinical trials for Luciras chlamydia and gonorrhea assays, said Debkishore Mitra, Ph.D, Chief Technology Officer and Co-Founder at Lucira Health.

Reproductive Hormones and Proteins Tests Market Research Report 2022 Featuring Danaher, Abbott Laboratories, Siemens Healthineers, Ortho-Clinical Diagnostics, F. Hoffmann-La Roche, & Tosoh - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 10, 2022
Medical Supplies, Hospitals, Baby, Maternity, Genetics, Biometrics, Other Health, Health, Consumer, General Health, Woman, Segment, Country, Industry, ASP, Hypogonadotropic hypogonadism, Hyperprolactinaemia, Man, Epidemiology, Review, COVID-19, Market access, Fertility, Chlamydia trachomatis, Cystic fibrosis, SWOT, SWOT analysis, Protein, Region, Neisseria gonorrhoeae, Hormone, Feed manufacturing, Healthcare, Milk, Retail, Neisseria, Forecast, Chlamydia

Reproductive Hormones and Proteins Tests Market Report is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.

Key Points: 
  • Reproductive Hormones and Proteins Tests Market Report is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.
  • The model discusses in detail the impact of COVID-19 on Reproductive Hormones and Proteins tests market for the year 2020 and beyond.
  • Annualized total Reproductive Hormones and Proteins Tests market revenue by segment and market outlooks from 2015- 2030.
  • Competitive dynamics insights and trends provided for Reproductive Hormones and Proteins Tests market.